|
Building international strategic partnerships
|
|
|
|
|
|
AcaHealth Pharma & Biotech company is focus on human experienced anti-aging herbs derived pure active ingredients drug discovery, aiming for aging related unmet medical need to treat these aging-related diseases.
Our middle to long-term goal is to collaborate with international pharmaceutical companies as strategic partners and pursuing development of first-in-class drugs for aging related diseases including chronic heart failure, chronic kidney disease, adjuvant for cancer chemotherapy, neurodegenerative diseases, insomnia, COPD(Chronic obstructive pulmonary diseases), dry eye, aged-related macular degeneration, and mitochondria related rare diseases.
Global Strategic Adviser
Ronald E. Law, PhD, JD
Dr. Law has over 30 years combined academic, pharma, and biotech experience in C-Suite Leadership roles, Business Development, Medical and Scientific Affairs, Corporate Strategy, External Innovation, and Competitive Intelligence.
He is currently serving as a Business Development Consultant for Scohia Pharmaceuticals (Yokohama, Japan), a clinical stage company focusing on metabolic diseases. From January 2019 to January 2020, Dr. Law served as Interim Chief Executive Officer for BioSpecifics Technologies Corporation, a NASDAQ-listed public commercial-stage pharmaceutical company, market cap ~ $400 M. Dr. Law was initially recruited to BioSpeciifc’s in November 2018 as SVP of Business Development. BioSpecifics was recently acquired by Endo Pharmaceuticals for ~ $600 M.
Prior to joining BioSpecifics, Dr. Law served as Chief Strategy Officer at Oramed Pharmaceuticals (Jerusalem, Israel), a clinical stage pharmaceutical company developing novel oral formulations for existing injectable therapeutics to treat type 1 and type 2 diabetes (e.g. oral insulin) from 2017-2018. A major focus of Dr. Law’s responsibilities was conducting business development activities in Japan.
In addition to Dr. Law’s CSO and CEO roles at Oramed and BioSpecific’s, he served as a Consultant for: AltaThera, a commercial stage cardiovascular disease company (Established Medical Affairs function); PharmaIn, a Seattle-based clinical stage company developing novel peptide therapeutics for heart failure and oncology through innovative drug delivery platforms ( Conducted Expert Outreach); Doctor Evidence (Santa Monica, CA), a medical evidence and analytics company focusing on harnessing real world evidence to improve treatment across multiple diseases (Served as Subject Matter Expert for diabetes); and Third Coast Therapeutics (Chicago, IL), a Northwestern University start-up discovering new approaches to treat metastatic cancer ( advised on preclinical discovery strategy).
From 2013-2016, Dr. Law was Vice President of New Frontier Science , Takeda Pharmaceuticals, leading a team of scientists and physician scientists searching for innovative and transformative technologies and biologies to create pioneering medicines. Prior to that position, Dr. Law was Head of the Global Scientific Affairs and Intelligence (GSAI) Team in the Strategic Product Planning Department in Takeda Corporate. Key responsibilities of his GSAI group included enhancing external scientific affairs (collaborations, partnerships etc.) between Takeda and academic and biotech scientists, as well as in acquisition and interpretation of scientific and business intelligence to inform and enable decision making by Senior Management.
In earlier years at Takeda, 2004 to 2013, Dr. Law held positions as Director and Senior Director of Medical and Scientific Product Evaluation in Medical and Scientific Affairs in Takeda Pharmaceuticals North America.
Dr. Law has conducted over 500 scientific evaluations/due diligences on various opportunities (mostly in cardiometabolic disease, CNS, and oncology) from biotechs, academia, and Big Pharma. He also served as the Scientific/BD Lead for both Due Diligence and Alliance Management on over 40 Takeda-academic/biotech research collaborations (Amylin, High Risk Plaque Initiative, and Sanford-Burnham Research Institute etc.). Dr. Law also served as the Scientific Lead on 3 major in-licensing deals that entered Takeda’s Commercial Portfolio: Contrave (Obesity), Amitiza (Constipation), and Brintellix (Major Depressive Disorder). In establishing Takeda’s first Competitive Intelligence Group, he led a combined Japan-US team of 14 to create data bases for all therapeutic areas which were shared directly with Takeda’s CEO and Senior Management. Dr. Law also developed a deep KOL Network in Cardiometabolic Disease and organized over 30 Advisory Boards during his Takeda career.
Prior to joining Takeda in 2004, Dr. Law was an Associate Professor of Medicine in the Division of Endocrinology, Diabetes and Hypertension at the University of California, Los Angeles, School of Medicine. His academic research focused on nuclear receptor function, particularly peroxisome proliferator-activated receptor gamma (PPARg), and signal transduction pathways involved in the vascular complications of type 2 diabetes resulting in over 100 peer-reviewed papers and reviews. Dr. Law served as principal investigator or co-investigator for numerous funded studies, among them: examinations of mechanism of action of thiazolidinediones on vascular smooth muscle cell growth, models of cardiovascular complications in diabetes, and the role of insulin resistance and hyperinsulinemia on vascular growth and atherosclerosis. He chaired or co-chaired numerous scientific sessions of the American Heart Association, the Council for High Blood Pressure Research, and the American Diabetes Association.
Dr. Law served as a member of the Editorial Boards for Arteriosclerosis, Thrombosis, and Vascular Biology; and Hypertension and was an ad hoc reviewer for over 20 professional journals. He received his BS and MS degrees from the University of Illinois at Chicago and a PhD in Molecular Biology from UCLA. Dr. Law’s postdoctoral training was at the Norris Cancer Center at the University of Southern California Keck School of Medicine in the Department of Neurosurgery working on glioblastoma. After completing his postdoc, Dr. Law joined the USC faculty in the Division of Endocrinology. Additionally, he earned a JD degree, magna cum laude, from the Whittier College School of Law where he was the recipient of 5 AmJur and 2 Center for Computer-Assisted Legal Education awards for top individual performance in 7 areas of law.
|
|
|
|
|
|
|
|